menu
    • menu
    [{"orgOrder":0,"company":"Metavant Sciences","sponsor":"Sumitomo Pharma Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Imeglimin Hydrochloride","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Metavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Metavant Sciences \/ Sumitomo Dainippon","highestDevelopmentStatusID":"10","companyTruncated":"Metavant Sciences \/ Sumitomo Dainippon"},{"orgOrder":0,"company":"Metavant Sciences","sponsor":"Poxel","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Termination","leadProduct":"Imeglimin Hydrochloride","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Metavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Metavant Sciences \/ Metavant","highestDevelopmentStatusID":"8","companyTruncated":"Metavant Sciences \/ Metavant"}]

    Find Clinical Drug Pipeline Developments & Deals by Metavant Sciences

    Menu

    Metavant Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Metavant Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Metavant Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imeglimin Hydrochloride

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Recipient : Poxel

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Poxel Regains Imeglimin Rights From Metavant

                            Details : Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any payment from Poxel as part of the return of the program.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 14, 2021

                            Lead Product(s) : Imeglimin Hydrochloride

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Recipient : Poxel

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Metavant Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Metavant Sciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imeglimin Hydrochloride

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Sumitomo Pharma Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Poxel Provides Update on Metavant Partnership with Imeglimin

                            Details : Metavant has conducted a strategic review and has decided not to move forward with the development of Imeglimin. Metavant will actively explore options for a potential out-licensing of Imeglimin rights for a period of 60 day.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 20, 2020

                            Lead Product(s) : Imeglimin Hydrochloride

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Sumitomo Pharma Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth